<!doctype html>
<html lang="es">
<head>
<meta charset="utf-8" />
<meta name="viewport" content="width=device-width, initial-scale=1" />
<title>Spanish Daily – Dec 11, 2025</title>
<meta name="color-scheme" content="light" />
<style>
  :root { --maxw: 800px; color-scheme: light; }
  html { -webkit-text-size-adjust: 100%; }
  body {
    margin: 0;
    padding: 0;
    background-color: #ffffff;
    color: #111111;
    font-family: system-ui,-apple-system,Segoe UI,Roboto,Helvetica,Arial,sans-serif,Apple Color Emoji,Segoe UI Emoji;
    line-height: 1.6;
    font-size: 18px;
  }
  header, main, footer { max-width: var(--maxw); margin: 0 auto; padding: 16px; }
  header { padding-top: 20px; }
  h1 { font-size: 1.4rem; margin: 0 0 8px; }
  .subtle { opacity: 0.72; font-size: 0.95rem; }
  .card { border: 1px solid rgba(0,0,0,0.08); border-radius: 12px; padding: 14px; margin: 12px 0; }
  .tip-word { all: unset; display: inline; position: relative; cursor: pointer;
    text-decoration: underline dotted; text-underline-offset: 3px;
    padding: 0 .1em; border-radius: .35em; background: rgba(255,235,59,.28); }
  .tooltip { position: fixed; padding: .48rem .6rem; background: rgba(0,0,0,.88); color: #fff;
    border-radius: .55rem; font-size: .95rem; line-height: 1.3; max-width: min(90vw, 26rem);
    z-index: 9999; box-shadow: 0 6px 18px rgba(0,0,0,.18); }
  .content { white-space: pre-line; }
  .card { margin-bottom: 1.5em; line-height: 1.6; }
  strong { display: inline-block; margin-top: .35em; }
  details { border: 1px solid rgba(0,0,0,0.08); border-radius: 12px; padding: 12px; }
  details + details, details + .card { margin-top: 12px; }
  summary { cursor: pointer; font-weight: 600; }
  summary::marker { content: ""; }
  summary::after { content: " ▸"; }
  details[open] summary::after { content: " ▾"; }
  .debug { position: fixed; bottom: 8px; right: 8px; font-size: 12px; opacity: .6; }
</style>
</head>
<body>
  <header>
    <h1>Spanish Daily</h1>
    <div class="subtle">Toca una palabra subrayada para ver la traducción. Toca fuera para cerrar.</div>
  </header>

  <main>
    <!-- Spanish first -->
    <section class="card content">
STORY

<span title="Semaglutide 2.4 mg (Wegovy)">Semaglutida 2.4 mg (Wegovy)</span> <span title="received an expanded indication">recibió una ampliación de indicación</span> <span title="by the FDA in 2024">por la FDA en 2024</span>. <span title="It is now indicated">Ahora está indicada</span> <span title="to reduce the risk">para reducir el riesgo</span> <span title="of major adverse cardiovascular events">de eventos cardiovasculares adversos mayores</span> (MACE) <span title="in adults with established cardiovascular disease">en adultos con enfermedad cardiovascular establecida</span> <span title="and obesity or overweight">y obesidad o sobrepeso</span>. <span title="This is based on">Esto se basa en</span> <span title="the SELECT cardiovascular outcomes trial">el estudio de resultados cardiovasculares SELECT</span>, <span title="conducted in">realizado en</span> <span title="more than 17,000 patients">más de 17,000 pacientes</span> <span title="with a history of">con antecedentes de</span> <span title="myocardial infarction">infarto de miocardio</span>, <span title="stroke">accidente cerebrovascular</span> <span title="or symptomatic peripheral arterial disease">o enfermedad arterial periférica sintomática</span> <span title="and a BMI of at least 27 kg/m²">y un IMC ≥27 kg/m²</span>.

1) <span title="Indication">Indicación</span>: <span title="Wegovy is now approved">Wegovy ahora está aprobado</span> <span title="to reduce the risk">para reducir el riesgo</span> <span title="of cardiovascular death">de muerte cardiovascular</span>, <span title="non-fatal myocardial infarction">infarto de miocardio no fatal</span> <span title="and non-fatal stroke">y accidente cerebrovascular no fatal</span> <span title="in adults with established cardiovascular disease">en adultos con enfermedad cardiovascular establecida</span> <span title="and BMI at least 27 kg/m²">e IMC ≥27 kg/m²</span>, <span title="together with diet and physical activity">junto con dieta y actividad física</span>.
2) <span title="Efficacy">Eficacia</span>: <span title="In SELECT">En SELECT</span>, <span title="semaglutide 2.4 mg weekly">semaglutida 2.4 mg semanal</span> <span title="reduced 3-point MACE">redujo el MACE de 3 puntos</span> <span title="by about 20 percent">en aproximadamente un 20%</span> <span title="versus placebo">frente a placebo</span> <span title="over about 3.3 years">durante unos 3.3 años</span>, <span title="in addition to standard preventive cardiovascular therapy">además de la terapia preventiva cardiovascular estándar</span>.
3) <span title="Population">Población</span>: <span title="Most had a history of myocardial infarction">La mayoría tenía antecedentes de infarto de miocardio</span>; <span title="baseline BMI was about 33 kg/m²">el IMC basal era de aproximadamente 33 kg/m²</span>; <span title="most were taking statins, antiplatelets, and ACEI/ARB">la mayoría tomaba estatinas, antiagregantes y IECA/ARA II</span>.
4) <span title="Weight and risk factors">Peso y factores de riesgo</span>: <span title="Average weight loss was about 9–10 percent">La pérdida de peso promedio fue de aproximadamente 9–10%</span> <span title="versus placebo">frente a placebo</span>, <span title="with modest improvements in systolic blood pressure">con mejoras modestas en presión arterial sistólica</span>, <span title="lipids, CRP, and glycemic parameters">lípidos, PCR y parámetros glucémicos</span>.
5) <span title="Dosing">Dosificación</span>: <span title="Use standard titration for obesity">Utilizar la titulación estándar para obesidad</span> <span title="up to 2.4 mg SC weekly">hasta 2.4 mg SC semanal</span>; <span title="continue long-term if tolerated">continuar a largo plazo si se tolera</span>.
6) <span title="Safety">Seguridad</span>: <span title="Gastrointestinal adverse effects">Los efectos adversos gastrointestinales</span> (<span title="nausea, vomiting, diarrhea">náuseas, vómitos, diarrea</span>) <span title="are common and dose-dependent">son comunes y dependientes de la dosis</span>; <span title="cholelithiasis, pancreatitis, and rarely acute kidney injury may occur">pueden ocurrir colelitiasis, pancreatitis y raramente lesión renal aguda</span>. <span title="Do not use in people with personal or family history of medullary thyroid carcinoma (MTC) or MEN2">No usar en personas con antecedentes personales o familiares de carcinoma medular de tiroides (MTC) o MEN2</span>.
7) <span title="Glycemia">Glucemia</span>: <span title="SELECT included non-diabetic patients">SELECT incluyó pacientes no diabéticos</span>; <span title="there were no signs of hypoglycemia without insulin or secretagogues">no hubo señales de hipoglucemia sin insulina o secretagogos</span>.
8) <span title="Integration">Integración</span>: <span title="Consider Wegovy for secondary prevention">Considere Wegovy para prevención secundaria</span> <span title="in patients with cardiovascular disease and obesity or overweight">en pacientes con enfermedad cardiovascular y obesidad o sobrepeso</span> <span title="who are already receiving guideline-based treatment">que ya reciben tratamiento según guías</span>, <span title="if cost, access, and patient preferences allow">si el costo, acceso y preferencias del paciente lo permiten</span>.

<span title="In practice">En la práctica</span>: <span title="Wegovy is now a cardioprotective agent">Wegovy ahora es un agente cardioprotector</span> <span title="in appropriate patients with established cardiovascular disease and obesity or overweight">en los pacientes adecuados con enfermedad cardiovascular establecida y obesidad o sobrepeso</span>, <span title="not just a weight loss drug">no solo un medicamento para bajar de peso</span>.

---
DIALOGUE

Narrator: <span title="Today, Dr. Kim sees Mr. Lee">Hoy, la Dra. Kim atiende al Sr. Lee</span>, <span title="who had a heart attack last year">quien tuvo un infarto el año pasado</span> <span title="and has a high BMI">y tiene un IMC alto</span>.
Physician: <span title="Hello, Mr. Lee">Hola, Sr. Lee</span>. <span title="Today I want to talk about">Hoy quiero hablar sobre</span> <span title="your heart and your weight">su corazón y su peso</span>.
Patient: <span title="That's fine, doctor">Está bien, doctora</span>. <span title="I try to eat better">Trato de comer mejor</span>, <span title="but my weight stays high">pero mi peso sigue alto</span>.
Physician: <span title="I know it's difficult">Sé que es difícil</span>. <span title="There is a new medicine called">Hay un medicamento nuevo llamado</span> <span title="semaglutide or Wegovy">semaglutida, o Wegovy</span>.
Patient: <span title="What does Wegovy do?">¿Qué hace Wegovy?</span>
Physician: <span title="Wegovy can help people">Wegovy puede ayudar a personas</span> <span title="with heart problems and overweight">con problemas cardíacos y sobrepeso</span>. <span title="It lowers the risk of heart attack and stroke">Disminuye el riesgo de infarto y accidente cerebrovascular</span>.
Patient: <span title="Is it like other weight loss medicines?">¿Es como otros medicamentos para bajar de peso?</span>
Physician: <span title="Wegovy helps you lose weight">Wegovy le ayuda a bajar de peso</span>, <span title="but it also protects your heart">pero también protege su corazón</span>. <span title="In a large study">En un estudio grande</span>, <span title="it reduced these risks">redujo estos riesgos</span> <span title="by about twenty percent">en aproximadamente un veinte por ciento</span>.
Patient: <span title="How is it taken?">¿Cómo se toma?</span>
Physician: <span title="It is an injection once a week">Es una inyección una vez por semana</span>. <span title="We gradually increase the dose">Vamos subiendo la dosis poco a poco</span> <span title="up to 2.4 mg">hasta 2.4 mg</span>.
Patient: <span title="Am I going to feel bad?">¿Me voy a sentir mal?</span>
Physician: <span title="Some people have stomach discomfort">Algunas personas tienen molestias estomacales</span> <span title="such as nausea">como náuseas</span>. <span title="We will watch for side effects">Vamos a estar atentos a los efectos secundarios</span>.
Patient: <span title="Can I take it with my other medicines?">¿Puedo tomarlo con mis otros medicamentos?</span>
Physician: <span title="Yes, you can use it">Sí, puede usarlo</span> <span title="together with your heart medicines">junto con sus medicamentos para el corazón</span>, <span title="such as statins">como las estatinas</span>. <span title="We will monitor you frequently">Lo vamos a controlar frecuentemente</span>.
Patient: <span title="Thank you, doctor">Gracias, doctora</span>. <span title="I want to try it if it helps my heart">Quiero intentarlo si ayuda a mi corazón</span>.
    </section>

    <!-- English below -->

    <details open class="card content">
      <summary>INGLÉS</summary>
STORY

Semaglutide 2.4 mg (Wegovy) got a 2024 FDA label expansion. It is now for lowering risk of major adverse cardiovascular events (MACE) in adults with established cardiovascular disease and obesity or overweight. This is based on the SELECT cardiovascular outcomes trial in over 17,000 patients with prior MI, stroke, or symptomatic PAD and BMI ≥27 kg/m².

1) Indication: Wegovy is now approved to lower risk of CV death, nonfatal MI, and nonfatal stroke in adults with established CVD and BMI ≥27 kg/m², plus diet and physical activity.
2) Efficacy: In SELECT, semaglutide 2.4 mg weekly lowered 3-point MACE by about 20% vs placebo over about 3.3 years, on top of standard CV preventive therapy.
3) Population: Most had prior MI; baseline BMI was about 33 kg/m²; most took statins, antiplatelets, and ACEi/ARB.
4) Weight and risk factors: Mean weight loss was about 9–10% vs placebo, with modest better systolic BP, lipids, CRP, and glycemic parameters.
5) Dosing: Use standard obesity titration to 2.4 mg SC weekly; continue long term if tolerated.
6) Safety: GI adverse effects (nausea, vomiting, diarrhea) are common and dose-related; cholelithiasis, pancreatitis, and rare acute kidney injury can occur. Do not use with personal or family history of MTC or MEN2.
7) Glycemia: SELECT used non-diabetic patients; no hypoglycemia signal without insulin or secretagogues.
8) Integration: Think about Wegovy for secondary prevention in patients with CVD and obesity or overweight who already have guideline-directed therapy, if cost, access, and patient preferences are okay.

In practice: Wegovy is now a cardioprotective agent in the right patients with established CVD and obesity or overweight, not only a weight-loss drug.

---
DIALOGUE

Narrator: Today, Dr. Kim sees Mr. Lee, who had a heart attack last year and has a high BMI.
Physician: Hello, Mr. Lee. I want to talk about your heart and weight today.
Patient: Okay, doctor. I try to eat better, but my weight is still high.
Physician: I know it is hard. There is a new medicine called semaglutide, or Wegovy.
Patient: What does Wegovy do?
Physician: Wegovy can help people with heart problems and high weight. It lowers risk of heart attack and stroke.
Patient: Is it like other weight loss drugs?
Physician: Wegovy helps you lose weight, but it also protects your heart. In a large study, it lowered these risks about twenty percent.
Patient: How do I take it?
Physician: It is a shot once a week. We slowly raise the dose to 2.4 mg.
Patient: Will I feel sick?
Physician: Some people have stomach problems like nausea. We will watch for side effects.
Patient: Can I take it with my other medicines?
Physician: Yes, you can use it with your heart medicines, like statins. We will check you often.
Patient: Thank you, doctor. I want to try if it helps my heart.
    </details>
  </main>

  <footer class="subtle">
    <div>© Dec 11, 2025 · Mezra.AI · Practica todos los días.</div>
  </footer>

  <div class="debug">EN: found</div>

  <!-- NEW: light cache-busting helper -->
  <script>
  (function() {
    // 1. Get the version tag from the URL, if present (?v=SHA...)
    var params = new URLSearchParams(window.location.search);
    var version = params.get('v');

    // 2. Read the debug indicator already inside your page
    var debug = document.querySelector('.debug');
    var debugText = debug ? debug.textContent.trim() : '';

    // 3. Heuristic: if version is missing or debug looks suspicious, force a one-time reload
    var isLikelyStale =
      !version ||
      debugText === '' ||
      debugText.indexOf('placeholder') !== -1 ||
      debugText.indexOf('not found') !== -1 ||
      debugText.length < 3;

    if (isLikelyStale) {
      if (!params.get('forceReload')) {
        params.set('forceReload', '1');
        var newUrl = window.location.pathname + '?' + params.toString();
        window.location.replace(newUrl);
      }
    }
  })();
  </script>

  <!-- Existing tooltip behavior -->
  <script>
  (function () {
    document.querySelectorAll('.content').forEach(function(container) {
      container.querySelectorAll('span[title]').forEach(function(span) {
        var text = span.textContent;
        var tip  = span.getAttribute('title');
        var btn  = document.createElement('button');
        btn.className = 'tip-word'; btn.type = 'button';
        btn.textContent = text; btn.setAttribute('data-tip', tip);
        span.replaceWith(btn);
      });
    });

    var openTip = null;
    function closeTip(){ if(openTip){ openTip.remove(); openTip = null; } }
    function showTip(target){
      closeTip();
      var tipText = target.getAttribute('data-tip') || '';
      if(!tipText) return;
      var bubble = document.createElement('div');
      bubble.className = 'tooltip';
      bubble.textContent = tipText;
      document.body.appendChild(bubble);
      var r = target.getBoundingClientRect();
      var m = 8, vw = innerWidth, vh = innerHeight;
      var rect = bubble.getBoundingClientRect();
      var tw = rect.width;
      var th = rect.height;
      var left = r.left, top = r.bottom + m;
      if (left + tw + m > vw) left = Math.max(m, vw - tw - m);
      if (left < m) left = m;
      if (top + th + m > vh) top = Math.max(m, r.top - th - m);
      bubble.style.left = left + 'px';
      bubble.style.top  = top + 'px';
      openTip = bubble;
    }

    document.addEventListener('click', function(e) {
      var word = e.target.closest('.tip-word');
      if (word){ if (openTip) closeTip(); else showTip(word); e.stopPropagation(); }
      else { closeTip(); }
    });
    document.addEventListener('touchstart', function(e) {
      if (!e.target.closest('.tip-word')) closeTip();
    }, { passive: true });
    addEventListener('scroll', closeTip, { passive: true });
    addEventListener('resize', closeTip);
    document.addEventListener('keydown', function(e) { if (e.key === 'Escape') closeTip(); });
  })();
  </script>
</body>
</html>